An assessment of breast cancer HER2, ER, and PR expressions based on mammography using deep learning with convolutional neural networks
Abstract Mammography is the recommended imaging modality for breast cancer screening. Expressions of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) are critical to the development of therapeutic strategies for breast cancer. In this study, a d...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-83597-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Mammography is the recommended imaging modality for breast cancer screening. Expressions of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) are critical to the development of therapeutic strategies for breast cancer. In this study, a deep learning model (CBAM ResNet-18) was developed to predict the expression of these three receptors on mammography without manual segmentation of masses. Mammography of patients with pathologically proven breast cancer was obtained from two centers. A deep learning-based model (CBAM ResNet-18) for predicting HER2, ER, and PR expressions was trained and validated using five-fold cross-validation on a training dataset. The performance of the model was further tested using an external test dataset. Area under receiver operating characteristic curve (AUC), accuracy (ACC), and F1-score were calculated to assess the ability of the model to predict each receptor. For comparison we also developed original ResNet-18 without attention module and VGG-19 with and without attention module. The AUC (95% CI), ACC, and F1-score were 0.708 (0.609, 0.808), 0.651, 0.528, respectively, in the HER2 test dataset; 0.785 (0.673, 0.897), 0.845, 0.905, respectively, in the ER test dataset; and 0.706 (0.603, 0.809), 0.678, 0.773, respectively, in the PR test dataset. The proposed model demonstrates superior performance compared to the original ResNet-18 without attention module and VGG-19 with and without attention module. The model has the potential to predict HER2, PR, and especially ER expressions, and thus serve as an adjunctive diagnostic tool for breast cancer. |
|---|---|
| ISSN: | 2045-2322 |